SKP-0141
/ SK Discovery
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 18, 2024
An Open-label Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SKP-0141 for the Treatment and Prophylaxis in Severe Hemophilia a Patients
(clinicaltrials.gov)
- P3 | N=55 | Not yet recruiting | Sponsor: SK Plasma Co., Ltd.
New P3 trial • Hematological Disorders • Hemophilia • Hemophilia A • Rare Diseases
1 to 1
Of
1
Go to page
1